|
1
|
Tan J, Jiang L, Cheng X, Wang C, Chen J,
Huang X, Xie P, Xia D, Wang R and Zhang Y: Association between
VEGF-460T/C gene polymorphism and clinical outcomes of
nasopharyngeal carcinoma treated with intensity-modulated radiation
therapy. Onco Targets Ther. 10:909–918. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W and Hu GH: Biomarkers for enhancing
the radiosensitivity of nasopharyngeal carcinoma. Cancer Biol Med.
12:23–32. 2015.PubMed/NCBI
|
|
3
|
Chan AT, Teo PM and Johnson PJ:
Nasopharyngeal carcinoma. Ann Oncol. 12:1007–1015. 2002. View Article : Google Scholar
|
|
4
|
Tulalamba W and Janvilisri T:
Nasopharyngeal carcinoma signaling pathway: An update on molecular
biomarkers. Int J Cell Biol. 2012:5946812012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wei WI and Kwong DL: Current management
strategy of nasopharyngeal carcinoma. Clin Exp Otorhinolaryngol.
3:1–12. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xue C, Tian Y, Zhang J, Zhao Y, Zhan J,
Fang W and Zhang L: Efficacy of BIBF 1120 or BIBF 1120 plus
chemotherapy on nasopharyngeal carcinoma in vitro and in vivo. Drug
Des Devel Ther. 10:1173–1180. 2016.PubMed/NCBI
|
|
7
|
Lee NY, Zhang Q, Pfister DG, Kim J, Garden
AS, Mechalakos J, Hu K, Le QT, Colevas AD, Glisson BS, et al:
Addition of bevacizumab to standard chemoradiation for
locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): A
phase 2 multi-institutional trial. Lancet Oncol. 13:172–180. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Simo R, Robinson M, Lei M, Sibtain A and
Hickey S: Nasopharyngeal carcinoma: United kingdom national
multidisciplinary guidelines. J Laryngol Otol. 130 Suppl:S97–S103.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu T, Tang J, Gu M, Liu L, Wei W and Yang
H: Recurrent nasopharyngeal carcinoma: A clinical dilemma and
challenge. Curr Oncol. 20:e406–e419. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suárez C, Rodrigo JP, Rinaldo A,
Langendijk JA, Shaha AR and Ferlito A: Current treatment options
for recurrent nasopharyngeal cancer. Eur Arch Otorhinolaryngol.
267:1811–1824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee V, Kwong D, Leung TW, Lam KO, Tong CC
and Lee A: Palliative systemic therapy for recurrent or metastatic
nasopharyngeal carcinoma-How far have we achieved? Crit Rev
Oncol/Hematol. 114:13–23. 2017. View Article : Google Scholar
|
|
12
|
He W, Zou C, Tian Z, Tan W, Shen W, Chen
J, Liu L and Xu R: Nasopharyngeal carcinoma treated with
bevacizumab combined with paclitaxel liposome plus cisplatin: A
case report and literature review. Onco Targets Ther. 10:67–72.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carla C, Daris F, Cecilia B, Francesca B,
Francesca C and Paolo F: Angiogenesis in head and neck cancer: A
review of the literature. J Oncol. 2012:3584722012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
NCCN Clinical Practice Guidelines in
Oncology: Head and neck cancers. 2017.version I.
|
|
15
|
Edge SB, Byrd DR and Compton CC: AJCC
Cancer Staging Handbook from the AJCC Cancer Staging Manual. (7th).
Springer. (New York, NY). 408. 2011.
|
|
16
|
Zhang L, Chen QY, Liu H, Tang LQ and Mai
HQ: Emerging treatment options for nasopharyngeal carcinoma. Drug
Des Devel Ther. 7:37–52. 2013.PubMed/NCBI
|
|
17
|
Matta A and Ralhan R: Overview of current
and future biologically based targeted therapies in head and neck
squamous cell carcinoma. Head Neck Oncol. 1:62009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sha D, He YJ, Wang WB and Han JQ:
Anti-nasopharyngeal carcinoma effect in vivo and in vitro of
Avastin and adenovirus-thymidine kinase suicide gene. Zhonghua Er
Bi Yan Hou Tou Jing Wai Ke Za Zhi. 42:526–532. 2007.(In Chinese).
PubMed/NCBI
|
|
19
|
Zhang C, Yang X, Zhang Q, Yang B, Xu L,
Qin Q, Zhu H, Liu J, Cai J, Tao G, et al: Berberine radiosensitizes
human nasopharyngeal carcinoma by suppressing hypoxia-inducible
factor-1α expression. Acta Otolaryngol. 134:185–192. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou S, Gu L, He J, Zhang H and Zhou M:
MDM2 regulates vascular endothelial growth factor mRNA
stabilization in hypoxia. Mol Cell Biol. 31:4928–4937. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stadler ME, Patel MR, Couch ME and Hayes
DN: Molecular biology of head and neck cancer: Risks and pathways.
Hematol Oncol Clin North Am. 22:1009–1124.vii. 2008. View Article : Google Scholar
|
|
22
|
Shi D, Guo W, Chen W, Fu L, Wang J, Tian
Y, Xiao X, Kang T, Huang W and Deng W: Nicotine promotes
proliferation of human nasopharyngeal carcinoma cells by regulating
α7AChR, ERK, HIF-1α and VEGF/PEDF signaling. PLoS One.
7:e438982012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Falchook GS, Wheler JJ, Naing A, Jackson
EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, et al:
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with
antiangiogenic therapy: A phase I trial of bortezomib plus
bevacizumab. Oncotarget. 5:10280–10292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wakisaka N, Wen QH, Yoshizaki T, Nishimura
T, Furukawa M, Kawahara E and Nakanishi I: Association of vascular
endothelial growth factor expression with angiogenesis and lymph
node metastasis in nasopharyngeal carcinoma. Laryngoscope.
109:810–814. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Druzgal CH, Chen Z, Yeh NT, Thomas GR,
Ondrey FG, Duffey DC, Vilela RJ, Ende K, McCullagh L, Rudy SF, et
al: A pilot study of longitudinal serum cytokine and angiogenesis
factor levels as markers of therapeutic response and survival in
patients with head and neck squamous cell carcinoma. Head Neck.
27:771–784. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Z and Xu XH: Combining antiangiogenic
therapy and radiation in nasopharyngeal carcinoma. Saudi Med J.
36:659–664. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun R, Wang X and Li X: Correlation
analysis of nasopharyngeal carcinoma TNM staging with serum EA IgA
and VCA IgA in EBV and VEGF-C and -D. Med Sci Monit. 21:2105–2109.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tung YT, Huang PW, Chou YC, Lai CW, Wang
HP, Ho HC, Yen CC, Tu CY, Tsai TC, Yeh DC, et al: Lung
tumorigenesis induced by human vascular endothelial growth factor
(hVEGF)-A165 overexpression in transgenic mice and amelioration of
tumor formation by miR-16. Oncotarget. 6:10222–10238. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xie M, He G, Wang R, Shi S, Chen J, Ye Y,
Xie L, Yi X and Tang A: Matrine-induced apoptosis of human
nasopharyngeal carcinoma cells via in vitro vascular endothelial
growth factor-A/extracellular signal-regulated kinase1/2 pathway
inactivation. Horm Metab Res. 46:556–560. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Toi M, Matsumoto T and Bando H: Vascular
endothelial growth factor: Its prognostic, predictive, and
therapeutic implications. Lancet Oncol. 2:667–673. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fujita K, Sano D, Kimura M, Yamashita Y,
Kawakami M, Ishiguro Y, Nishimura G, Matsuda H and Tsukuda M:
Anti-tumor effects of bevacizumab in combination with paclitaxel on
head and neck squamous cell carcinoma. Oncol Rep. 18:47–51.
2007.PubMed/NCBI
|
|
32
|
Vaklavas C, Lenihan D, Kurzrock R and
Tsimberidou AM: Anti-vascular endothelial growth factor therapies
and cardiovascular toxicity: What are the important clinical
markers to target? Oncologist. 15:130–141. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li Y, Lu J, Zhou S, Wang W, Tan G, Zhang
Z, Dong Z, Kang T and Tang F: Clusterin induced by
N,N'-Dinitrosopiperazine is involved in nasopharyngeal carcinoma
metastasis. Oncotarget. 7:5548–5563. 2016.PubMed/NCBI
|
|
34
|
Chen HH, Weng BQ, Cheng KJ, Liu HY, Wang
SQ and Lu YY: Effect of the vascular endothelial growth factor
expression level on angiopoietin-2-mediated nasopharyngeal
carcinoma growth. Vasc Cell. 6:42014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Grunstein J, Roberts WG, Mathieu-Costello
O, Hanahan D and Johnson RS: Tumor-derived expression of vascular
endothelial growth factor is a critical factor in tumor expansion
and vascular function. Cancer Res. 59:1592–1598. 1999.PubMed/NCBI
|
|
36
|
Li YH, Hu CF, Shao Q, Huang MY, Hou JH,
Xie D, Zeng YX and Shao JY: Elevated expressions of survivin and
VEGF protein are strong independent predictors of survival in
advanced nasopharyngeal carcinoma. J Transl Med. 6:12008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hui HP, Chan AT, Pezzella F, Turley H, To
KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, et al: Coexpression of
Hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX,
and vascular endothelial growth factor in nasopharyngeal carcinoma
and relationship to survival. Clin Cancer Res. 8:2595–2604.
2002.PubMed/NCBI
|
|
38
|
Sung FL, Hui EP, Tao Q, Li H, Tsui NB, Lo
YM, Ma BB, To KF, Harris AL and Chan AT: Genome-wide expression
analysis using microarray identified complex signaling pathways
modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett.
253:74–88. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cohen EE, Davis DW, Karrison TG, Seiwert
TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, et al:
Erlotinib and bevacizumab in patients with recurrent or metastatic
squamous cell carcinoma of the head and neck: A phase I/II study.
Lancet Oncol. 10:247–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang L, Liu L, Xu Z, Liao W, Feng D, Dong
X, Xu S, Xiao L, Lu J, Luo X, et al: EBV-LMP1 targeted DNAzyme
enhances radiosensitivity by inhibiting tumor angiogenesis via the
JNKs/HIF-1 pathway in nasopharyngeal carcinoma. Oncotarget.
6:5804–5817. 2015.PubMed/NCBI
|
|
41
|
Qian CN, Zhang CQ, Guo X, Hong MH, Cao SM,
Mai WY, Min HQ and Zeng YX: Elevation of serum vascular endothelial
growth factor in male patients with metastatic nasopharyngeal
carcinoma. Cancer. 88:255–261. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Le QT and Raben D: Integrating
biologically targeted therapy in head and neck squamous cell
carcinomas. Semin Radiat Oncol. 19:53–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qian CN, Min HQ, Lin HL, Hong MH and Ye
YL: Primary study in experimental antiangiogenic therapy of
nasopharyngeal carcinoma with AGM-1470 (TNP-470). J Laryngol Otol.
112:849–853. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wilken R, Veena MS, Wang MB and Srivatsan
ES: Curcumin: A review of anti-cancer properties and therapeutic
activity in head and neck squamous cell carcinoma. Mol Cancer.
10:122011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Specenier P and Vermorken JB: Biologic
therapy in head and neck cancer: A road with hurdles. ISRN Oncol.
2012:1637522012.PubMed/NCBI
|
|
46
|
Echarri MJ, Lopez-Martin A and Hitt R:
Targeted therapy in locally advanced and Recurrent/metastatic head
and neck squamous cell carcinoma (LA-R/M HNSCC). Cancers (Basel).
8:pii:E272016. View Article : Google Scholar
|
|
47
|
Schmidt B, Lee HJ, Ryeom S and Yoon SS:
Combining bevacizumab with radiation or chemoradiation for solid
tumors: A review of the scientific rationale, and clinical trials.
Curr Angiogenes. 1:169–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li J, Zhao Z, Wu X, Yao J, Ma L, Ye R, Niu
B, Liang L, Zhao X and Wang Q: Bevacizumab plus cisplatin and
helical tomotherapy in treatment of locally advanced nasopharyngeal
carcinoma. Onco Targets Ther. 8:1315–1319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Spratt DE and Lee N: Current and emerging
treatment options for nasopharyngeal carcinoma. Onco Targets Ther.
5:297–308. 2012.PubMed/NCBI
|
|
50
|
Seiwert TY, Haraf DJ, Cohen EE, Stenson K,
Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX and
Vokes EE: Phase I study of bevacizumab added to fluorouracil- and
hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis
head and neck cancer. J Clin Oncol. 26:1732–1741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Pfister DG, Lee NY, Sherman E, Lisa D,
Carlson D, Stambuk H, Shen R, Kraus D, Shah J and Fury MG: Phase II
study of bevacizumab (B) plus cisplatin (C) plus
intensity-modulated radiation therapy (IMRT) for locoregionally
advanced head and neck squamous cell cancer (HNSCC): Preliminary
results. J Clin Oncol. 27:60132009.
|
|
52
|
Fury MG, Lee NY, Sherman E, Lisa D, Kelly
K, Lipson B, Carlson D, Stambuk H, Haque S, Shen R, et al: A phase
2 study of bevacizumab with cisplatin plus intensity-modulated
radiation therapy for stage III/IVB head and neck squamous cell
cancer. Cancer. 118:5008–5014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Meluch AA, Spigel D, Burris HA, Lane C,
Peyton JD, Shipley D, Rubin M, Stipanov M, Greco FA and Hainsworth
JD: Combined modality therapy with radiation therapy (RT),
chemotherapy, bevacizumab, and erlotinib in the treatment of
patients (pts) with locally advanced squamous carcinoma of the head
and neck. J Clin Oncol. 27 (15 Suppl):60122009.PubMed/NCBI
|
|
54
|
Lu J, Zhang K, Chen S and Wen W: Grape
seed extract inhibits VEGF expression via reducing HIF-1alpha
protein expression. Carcinogenesis. 30:636–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hoffmann TK: Systemic therapy strategies
for head-neck carcinomas: Current status. GMS Curr Top
Otorhinolaryngol Head Neck Surg. 11:Doc032012.PubMed/NCBI
|
|
56
|
Zhang JW, Qin T, Hong SD, Zhang J, Fang
WF, Zhao YY, Yang YP, Xue C, Huang Y, Zhao HY, et al: Multiple
oncogenic mutations related to targeted therapy in nasopharyngeal
carcinoma. Chin J Cancer. 34:177–183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chan SL and Ma BB: Novel systemic
therapeutic for nasopharyngeal carcinoma. Expert Opin Ther Targets.
16 Suppl 1:S63–S68. 2012. View Article : Google Scholar : PubMed/NCBI
|
